Study of Alzheimer Biomarkers in Cerebrospinal Fluid for People with Cognitive Disorders Including Various Neurodegenerative Dementias

What this Trial Is About

Cognitive neurodegenerative diseases, such as Alzheimers disease and other dementias, pose significant public health challenges due to difficulties in making accurate diagnoses during a patients lifetime. This research aims to better understand how biomarkers found in cerebrospinal fluid CSF can improve diagnosis accuracy for these diseases, which often share overlapping symptoms and progress slowly over many years. The study also seeks to identify biomarkers specific to different neurodegenerative conditions to aid in their diagnosis. Participants with cognitive disorders who undergo a lumbar puncture as part of their diagnostic process at the memory center are observed in this study. The lumbar puncture procedure collects cerebrospinal fluid, which is analyzed for Alzheimers disease biomarkers and potentially others related to different neurodegenerative diseases. This observational study includes patients with various cognitive impairments who are monitored without altering their standard clinical care. During the study, researchers collect and analyze cerebrospinal fluid samples over a one-year period. They also work on establishing new clinical study collaborations within the same timeframe. The study involves reviewing clinical data and diagnosis information to improve understanding of biomarker use in neurodegenerative disease diagnosis. Participant involvement includes routine lumbar puncture procedures and clinical assessments as part of their healthcare, with data collected for research purposes.

Cerebro Spinal Fluid Collection (CSF)